Zealand Abandons Sanofi Diabetes Drug in $205 Million Deal with Royalty Pharma

Copenhagen-based Zealand Pharma is selling future royalty streams and $85 million in potential commercial milestones for two diabetes drugs, Soliqua/Suliqua and Lyxumia/Adlyxin, to New York-based Royalty Pharma. Soliqua is a combination of insulin and Ze https://www.biospace.com/article/-am6a-zealand-abandons-sanofi-diabetes-drug-in-205-million-deal-with-royalty-pharma/